News | Chosa Oncology

Apr 03, 2024

CHOSA has carried out a directed issue of SEK 5,58 million to fund KOL-initiated DRP validation studies and to increase business development activities

Regulatory press release: The board of CHOSA Oncology AB (publ) (CHOSA or the Company) has today, 3. April 2024, performed a directed issue of 6 070 233 shares at a price of SEK 0,92 per share. The subscription price per sha...[Read more]

More News

2024

Latest

Apr 03, 2024

CHOSA har genomfört en riktad emission på 5,58 miljoner SEK för att finansiera KOL-initierade DRP-valideringsstudier och för ökade affärsutvecklingsaktiviteter

Regulatory press release: Styrelsen för CHOSA Oncology AB (publ) (CHOSA eller Bolaget) har idag, den 3:e april 2024, genomfört en riktad emission av 6...[Read more]

Mar 28, 2024

Chosa Oncology – Appoints Chief Commercial Officer and new Chief Financial Officer

Regulatory press release: 28 March 2024 CHOSA Oncology – today announced the appointment of Claus Frisenberg Pedersen as Chief Commercial Officer and...[Read more]

Mar 28, 2024

Chosa Oncology - Utser Chief Commercial Officer och ny Chief Financial Officer

Regulatory press release: Marts 28, 2024 CHOSA Oncology meddelade idag utnämningen av Claus Frisenberg Pedersen som Chief Commercial Officer och Gert...[Read more]

Feb 29, 2024

CHOSA Oncology AB - Bokslutskommuniké januari-december 2023

Regulatory press release: [Read more]

Feb 08, 2024

CHOSA Oncology AB’s postpones publication of the interim report Q4 2024

Regulatory press release: CHOSA Oncology announced today, 8th February 2024, the decision to postpone the release of its interim report for the fourth...[Read more]

Feb 08, 2024

CHOSA Oncology AB senarelägger publiceringen av delårsrapporten för fjärde kvartalet 2024

Regulatory press release: CHOSA Oncology AB har idag, 8. februari 2024, beslutat att senarelägga publiceringen av delårsrapporten avseende fjärde kvar...[Read more]

News published before 2023 >>